CO6491059A2 - Diferenciacion de las celulas madre mesenquimales - Google Patents

Diferenciacion de las celulas madre mesenquimales

Info

Publication number
CO6491059A2
CO6491059A2 CO12007861A CO12007861A CO6491059A2 CO 6491059 A2 CO6491059 A2 CO 6491059A2 CO 12007861 A CO12007861 A CO 12007861A CO 12007861 A CO12007861 A CO 12007861A CO 6491059 A2 CO6491059 A2 CO 6491059A2
Authority
CO
Colombia
Prior art keywords
mesenquimal
differentiation
mother cells
joint
mammal
Prior art date
Application number
CO12007861A
Other languages
English (en)
Spanish (es)
Inventor
Kristen Johnson
Lori Jennings
Peter G Schultz
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6491059(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of CO6491059A2 publication Critical patent/CO6491059A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO12007861A 2009-07-14 2012-01-19 Diferenciacion de las celulas madre mesenquimales CO6491059A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
CO6491059A2 true CO6491059A2 (es) 2012-07-31

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12007861A CO6491059A2 (es) 2009-07-14 2012-01-19 Diferenciacion de las celulas madre mesenquimales

Country Status (30)

Country Link
US (4) US9139633B2 (cg-RX-API-DMAC7.html)
EP (1) EP2453921B1 (cg-RX-API-DMAC7.html)
JP (1) JP5602850B2 (cg-RX-API-DMAC7.html)
KR (3) KR101590834B1 (cg-RX-API-DMAC7.html)
CN (2) CN102625830B (cg-RX-API-DMAC7.html)
AU (1) AU2010273570B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012000914B8 (cg-RX-API-DMAC7.html)
CA (1) CA2767826C (cg-RX-API-DMAC7.html)
CL (1) CL2012000091A1 (cg-RX-API-DMAC7.html)
CO (1) CO6491059A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120024A (cg-RX-API-DMAC7.html)
CU (1) CU24042B1 (cg-RX-API-DMAC7.html)
EA (1) EA023073B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011604A (cg-RX-API-DMAC7.html)
ES (1) ES2541217T3 (cg-RX-API-DMAC7.html)
GT (1) GT201200011A (cg-RX-API-DMAC7.html)
IL (2) IL217383A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN00572A (cg-RX-API-DMAC7.html)
MA (1) MA33423B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012000707A (cg-RX-API-DMAC7.html)
MY (1) MY160951A (cg-RX-API-DMAC7.html)
NZ (1) NZ597306A (cg-RX-API-DMAC7.html)
PE (2) PE20160507A1 (cg-RX-API-DMAC7.html)
PL (1) PL2453921T3 (cg-RX-API-DMAC7.html)
PT (1) PT2453921E (cg-RX-API-DMAC7.html)
SG (1) SG177318A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000655A1 (cg-RX-API-DMAC7.html)
UA (1) UA104031C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011008773A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200078B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN110198447B (zh) 2011-11-08 2022-01-04 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
WO2014004465A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
CA2904160C (en) 2013-03-15 2022-08-23 The California Institute For Biomedical Research Phenyl sulfonamide derivatives and use thereof in the treatment of arthritis
FI3143026T3 (fi) 2014-05-13 2024-10-10 Novartis Ag Yhdisteitä ja koostumuksia kondrogeneesin indusoimiseksi
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
JP7541810B2 (ja) 2016-03-03 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
KR20190084287A (ko) 2016-11-14 2019-07-16 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US12257243B2 (en) 2018-12-06 2025-03-25 Novartis Ag 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2291198T3 (es) * 1999-07-20 2008-03-01 Genentech, Inc. Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US7687460B2 (en) * 2000-10-16 2010-03-30 Genentech, Inc, Methods of treatment using wisp polypeptides
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
AU2003270454B2 (en) * 2002-09-09 2010-05-20 Nektar Therapeutics Water-soluble polymer alkanals
EP1860186B1 (en) * 2003-03-10 2010-11-17 Japan Science And Technology Agency Method for distinguishing mesenchymal stem cells using different markers
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
JP5269411B2 (ja) * 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
IN2012DN00572A (cg-RX-API-DMAC7.html) 2015-06-12
US10064918B2 (en) 2018-09-04
WO2011008773A2 (en) 2011-01-20
GT201200011A (es) 2013-12-10
KR20180000337A (ko) 2018-01-02
MY160951A (en) 2017-03-31
CA2767826A1 (en) 2011-01-20
PL2453921T3 (pl) 2015-11-30
EP2453921A2 (en) 2012-05-23
EA023073B1 (ru) 2016-04-29
PE20160507A1 (es) 2016-05-20
EA201200118A1 (ru) 2012-09-28
KR101590834B1 (ko) 2016-02-12
TN2011000655A1 (en) 2013-05-24
AU2010273570A1 (en) 2012-02-02
BR112012000914A8 (pt) 2017-12-19
CL2012000091A1 (es) 2012-10-26
US11241482B2 (en) 2022-02-08
IL217383A0 (en) 2012-02-29
MX2012000707A (es) 2012-03-21
US20160213748A1 (en) 2016-07-28
CN102625830B (zh) 2016-03-02
CN105601728A (zh) 2016-05-25
US10555990B2 (en) 2020-02-11
US20190000922A1 (en) 2019-01-03
WO2011008773A3 (en) 2011-08-25
ZA201200078B (en) 2013-01-30
UA104031C2 (uk) 2013-12-25
JP5602850B2 (ja) 2014-10-08
CR20120024A (es) 2012-06-11
CU20120007A7 (es) 2013-02-26
MA33423B1 (fr) 2012-07-03
BR112012000914B1 (pt) 2021-04-06
AU2010273570B2 (en) 2014-07-03
PE20120570A1 (es) 2012-05-19
HK1164169A1 (en) 2012-09-21
CN102625830A (zh) 2012-08-01
CN105601728B (zh) 2020-01-10
NZ597306A (en) 2014-03-28
ES2541217T3 (es) 2015-07-16
EP2453921B1 (en) 2015-05-27
PT2453921E (pt) 2015-09-25
IL217383A (en) 2016-08-31
US9139633B2 (en) 2015-09-22
US20120177644A1 (en) 2012-07-12
US20200108122A1 (en) 2020-04-09
SG177318A1 (en) 2012-03-29
IL247310B (en) 2018-04-30
EP2453921A4 (en) 2012-12-19
CA2767826C (en) 2015-11-24
KR20120029472A (ko) 2012-03-26
ECSP12011604A (es) 2012-06-29
KR20160015403A (ko) 2016-02-12
BR112012000914A2 (pt) 2017-08-08
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
BR112012000914B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
ES2692918T3 (es) Métodos y composiciones para producir aldehídos grasos
PH12012500849A1 (en) Mycobacterial vaccines
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
IN2014KN01713A (cg-RX-API-DMAC7.html)
IN2014KN01714A (cg-RX-API-DMAC7.html)
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AR083354A1 (es) Polipeptidos variantes cbh i (celobiohidrolasas i) con reducida inhibicion de producto
UA110806C2 (uk) Мікобактеріальна антигенна композиція
MX2015004060A (es) 3-epimerasa.
EA201000327A1 (ru) Белок
NZ607069A (en) Modified relaxin polypeptides and their uses
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
CL2012001609A1 (es) Polipéptido de fusión contra tumor inducido por virus epstein-barr (eb) formado por la unión de polipéptido mutante de colicina ia, el cual pude formar canales iónicos, y que tiene las mutaciones g11a, h22g, a26g, v31l y h40d, con un anticuerpo anti-virus eb o un polipéptido mimético de anticuerpo anti-virus eb; gen codificante de dicho polipéptido; plásmido de recombinación que comprende dicho gen; método de preparación de dicho polipéptido; uso médico de dicho polipéptido; polipéptido mutante de colicina ia con sec id n°24 (con mutaciones mutaciones g11a, h22g, a26g, v31l y h40d); gen codificante de dicho polipéptido; uso médico de dicho gen.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)